xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

322

KUANetal.

TABLE XXVI.3 (Continued)

Clinical endpoints 1. OS 2. Disease

Study

Year LOE Study design Study groups

Conclusion

Li et al. 1777

Achievement of complete response only prognostic factor that was significant

2004 4

Retrospective case series

77 patients with

sinonasal ENKTL treated at a single center; 12 treated withRT, 28 chemotherapy alone, 37 treated with CRT (RT 40–50Gy; chemotherapy CHOP, E-CHOP, or ESHAP) ENKTL treated at a single institution with combined RT (three of the total 23 patients including other lymphomas received chemotherapy, unspecified which pathology they represented) ENKTL treated at a single institution (14 within the nasal cavityor nasopharynx). Seven received RT only, four chemotherapy only, nine CRT (chemotherapy 6weeks Adriamycin containing regimen, RT 40–45 Gy) 20 patients with stage I or II ENKTL treated at a single institution. Six treated with RT (two subsequently received chemotherapy), two received CRT, and 12 received initial chemotherapy (CHOPor CHOP-like) (nine of which went on to receive RT) Eight patients with 20 patients with

response

Proulx et al. 1766

2003 4

Retrospective case series

OS

1. 5-year estimated OS was 88% 2. Early stage responded well to RT, but distant failure remains a problem

Hahnet al. 1773

1. Complete remission was 65% for ENKTL 2. OS was 13 months for ENKTL 3. Difference between treatment modalities not calculated

1. OS 2. Treatment response

2002 4

Retrospective case series

Ribrag et al. 1845

2001 4

Retrospective case series

OS

Initial chemotherapy for early disease performed worse than upfrontRT

(Continues)